Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Imatinib
Drug ID BADD_D01136
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status approved
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D08066
MeSH ID D000068877
PubChem ID 5291
TTD Drug ID D0AZ3C
NDC Product Code 63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII BKJ8M8G5HI
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C29H31N7O
CAS Registry Number 152459-95-5
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral infarction24.04.06.002; 17.08.01.0040.000951%Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.0030.000112%
Cerebrovascular disorder24.03.05.002; 17.08.02.0020.000168%Not Available
Cervix carcinoma16.12.01.001; 21.06.02.0010.000112%Not Available
Cheilitis23.03.03.025; 07.05.01.001--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Chloasma23.05.01.001; 18.08.02.0020.000224%Not Available
Cholangiocarcinoma16.07.01.002; 09.04.02.0090.000168%Not Available
Cholangitis09.02.01.0020.000168%Not Available
Cholecystitis09.03.01.0010.000358%
Cholelithiasis09.03.01.002--Not Available
Chromaturia20.02.01.002--
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.0010.000280%Not Available
Chronic myeloid leukaemia16.01.07.001; 01.10.07.0010.007947%Not Available
Chronic myelomonocytic leukaemia16.01.04.004; 01.10.04.0040.000168%Not Available
Cold sweat08.01.03.024; 23.02.03.002--Not Available
Colitis07.08.01.0010.000907%
Colon cancer16.13.01.001; 07.21.01.0010.000839%Not Available
Compartment syndrome24.04.05.006; 15.05.05.0050.000112%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctival haemorrhage24.07.05.001; 06.07.01.0010.001164%Not Available
Conjunctival oedema06.04.01.0010.000112%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Conjunctivitis allergic06.04.01.003; 10.01.04.0020.000168%Not Available
Constipation07.02.02.001--
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery occlusion12.02.01.036; 24.04.04.013; 02.02.01.0060.000168%Not Available
Cough22.02.03.001--
Crepitations08.01.03.0060.000112%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene